Search Results

[The persistence and the reasons for discontinuation of daily teriparatide self-injection (dTPTD); difference between inpatients and outpatients when started dTPTD].

Subjects: Teriparatide*/Teriparatide*/Teriparatide*/therapeutic use ; Osteoporosis*; Humans

• Source: Nihon Ronen Igakkai zasshi. Japanese journal of geriatrics [Nihon Ronen Igakkai Zasshi] 2024; Vol. 61 (1), pp. 87-89.Publisher: Japan Geriatrics Society Country of Publication: Japan NLM ID: 7507332 Publication Model: Print Cited Medium: Internet ISSN: 0300-9173

Record details

Effects of four-year cyclic versus two-year daily teriparatide treatment on volumetric bone density and bone strength in postmenopausal women with osteoporosis.

• Authors : Ganapathy A; Institute of Human Nutrition, Columbia University, New York, NY, United States of America.; Nieves JW

Subjects: Bone Density Conservation Agents*/Bone Density Conservation Agents*/Bone Density Conservation Agents*/administration & dosage ; Bone Density Conservation Agents*/Bone Density Conservation Agents*/Bone Density Conservation Agents*/therapeutic use ; Osteoporosis*/Osteoporosis*/Osteoporosis*/drug therapy

• Source: Bone [Bone] 2023 Feb; Vol. 167, pp. 116618. Date of Electronic Publication: 2022 Nov 21.Publisher: Elsevier Science Country of Publication: United States NLM ID: 8504048 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

Teriparatide Followed by Denosumab in Premenopausal Idiopathic Osteoporosis: Bone Microstructure and Strength by HR-pQCT.

• Authors : Agarwal S; Department of Medicine, Columbia University Vagelos College of Physicians & Surgeons, New York, NY, USA.; Shiau S

Subjects: Osteoporosis*/Osteoporosis*/Osteoporosis*/drug therapy ; Teriparatide*/Teriparatide*/Teriparatide*/pharmacology ; Teriparatide*/Teriparatide*/Teriparatide*/therapeutic use

• Source: Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research [J Bone Miner Res] 2023 Jan; Vol. 38 (1), pp. 35-47. Date of Publisher: American Society for Bone and Mineral Research Country of Publication: United States NLM ID: 8610640 Publication Model: Print-Electronic Cited

Record details

Enhanced oral absorption of teriparatide with therapeutic potential for management of osteoporosis.

• Authors : Subedi L; Department of Biomedicine, Health & Life Convergence Sciences, BK21 Four, Biomedical and Healthcare Research Institute, Mokpo National University, Jeonnam 58554, Republic of Korea.; Pandey P

Subjects: Osteoporosis*/Osteoporosis*/Osteoporosis*/drug therapy ; Teriparatide*/Teriparatide*/Teriparatide*/therapeutic use; Adenosine Monophosphate/Adenosine Monophosphate/Adenosine Monophosphate/therapeutic use

• Source: Journal of controlled release : official journal of the Controlled Release Society [J Control Release] 2022 Sep; Vol. 349, pp. 502-519. Date of Electronic Publication: 2022 Jul 19.Publisher: Elsevier Science Publishers Country of Publication: Netherlands NLM ID: 8607908 Publication Model: Print-Electronic Cited Medium: Internet

Record details

Efficacy and Safety of Teriparatide in Beta-Thalassemia Major Associated Osteoporosis: A Real-Life Experience.

• Authors : Gagliardi I; Section of Endocrinology, Geriatrics & Internal Medicine, Dept of Medical Sciences, University of Ferrara, Via Fossato di Mortara 64/B, 44121, Ferrara, Italy.; Celico M

Subjects: Bone Density Conservation Agents*/Bone Density Conservation Agents*/Bone Density Conservation Agents*/adverse effects ; Bone Density Conservation Agents*/Bone Density Conservation Agents*/Bone Density Conservation Agents*/therapeutic use ; Osteoporosis*/Osteoporosis*/Osteoporosis*/complications

• Source: Calcified tissue international [Calcif Tissue Int] 2022 Jul; Vol. 111 (1), pp. 56-65. Date of Electronic Publication: 2022 Mar 04.Publisher: Springer Verlag Country of Publication: United States NLM ID: 7905481 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

Impaired bone strength and bone microstructure in a novel early-onset osteoporotic rat model with a clinically relevant PLS3 mutation.

• Authors : Hu J; Department of Endocrinology, Key Laboratory of Endocrinology, National Health and Family Planning Commission, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.; Zhou B

Subjects: Teriparatide* ; Osteoporosis*/Osteoporosis*/Osteoporosis*/drug therapy ; Osteoporosis*/Osteoporosis*/Osteoporosis*/genetics

• Source: ELife [Elife] 2023 Apr 21; Vol. 12. Date of Electronic Publication: 2023 Apr 21.Publisher: eLife Sciences Publications, Ltd Country of Publication: England NLM ID: 101579614 Publication Model: Electronic Cited Medium: Internet

Record details

Extracorporeal Shock Wave Combined with Teriparatide-Loaded Hydrogel Injection Promotes Segmental Bone Defects Healing in Osteoporosis.

• Authors : Chen Q; Department of Orthopedic Surgery, Zhejiang Provincial People's Hospital, People's Hospital of Hangzhou Medical College, Hangzhou, 310014, People's Republic of China.; Xia C

Subjects: Bone Regeneration*/Bone Regeneration*/Bone Regeneration*/drug effects ; Extracorporeal Shockwave Therapy* ; Hydrogels*/Hydrogels*/Hydrogels*/administration & dosage

• Source: Tissue engineering and regenerative medicine [Tissue Eng Regen Med] 2021 Dec; Vol. 18 (6), pp. 1021-1033. Date of Electronic Publication: 2021 Aug 24.Publisher: Springer International Publishing co-published with Korean Tissue Engineering and Regenerative Medicine Country of Publication: Korea (South) NLM ID:

Record details

Quantitative lateral flow immunoassay for rapid detection of procollagen type I N-terminal propeptide in the monitoring of osteoporosis treatment.

• Authors : Chen CA; Department of Orthopaedic Surgery, Spine Section and Bone and Joint Research Center, Chang Gung Memorial Hospital, Taoyuan, Taiwan.; Chiu PY

Subjects: Teriparatide*/Teriparatide*/Teriparatide*/therapeutic use ; Osteoporosis*/Osteoporosis*/Osteoporosis*/diagnostic imaging ; Osteoporosis*/Osteoporosis*/Osteoporosis*/drug therapy

• Source: Analytica chimica acta [Anal Chim Acta] 2023 Jan 25; Vol. 1239, pp. 340695. Date of Electronic Publication: 2022 Dec 02.Publisher: Elsevier Country of Publication: Netherlands NLM ID: 0370534 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

Four-Year Teriparatide Followed by Denosumab vs. Continuous Denosumab in Glucocorticoid-Induced Osteoporosis Patients With Prior Bisphosphonate Treatment.

• Authors : Hirooka Y; Department of Rheumatology, Kindai University Nara Hospital, Nara, Japan.; Department of Hematology and Rheumatology, Kindai University School of Medicine, Osaka, Japan.

Subjects: Bone Density Conservation Agents/Bone Density Conservation Agents/Bone Density Conservation Agents/*therapeutic use ; Denosumab/Denosumab/Denosumab/*therapeutic use ; Diphosphonates/Diphosphonates/Diphosphonates/*therapeutic use

• Source: Frontiers in endocrinology [Front Endocrinol (Lausanne)] 2021 Sep 27; Vol. 12, pp. 753185. Date of Electronic Publication: 2021 Sep 27 (Print Publication: 2021).Publisher: Frontiers Research Foundation] Country of Publication: Switzerland NLM ID: 101555782 Publication Model: eCollection Cited Medium: Print

Record details

Efficacy of once-weekly teriparatide in patients with glucocorticoid-induced osteoporosis: the TOWER-GO study.

• Authors : Tanaka I; Nagoya Rheumatology Clinic, Initiative for Rheumatology and Osteoporosis, Nagoya, Japan.; Tanaka Y

Subjects: Glucocorticoids/Glucocorticoids/Glucocorticoids/*adverse effects ; Osteoporosis/Osteoporosis/Osteoporosis/*chemically induced ; Osteoporosis/Osteoporosis/Osteoporosis/*drug therapy

• Source: Journal of bone and mineral metabolism [J Bone Miner Metab] 2021 May; Vol. 39 (3), pp. 446-455. Date of Electronic Publication: 2020 Nov 19.Publisher: Japanese Society of Bone and Mineral Metabolism Country of Publication: Japan NLM ID: 9436705 Publication Model: Print-Electronic Cited Medium:

Record details